Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Investor Presentation (July 2026)
18 slides from Vivani Medical's investor presentation, Jul 16, 2026
Slide 1: Guaranteed Adherence. Better Outcomes.
o0Ce,. Vivant Nasdaq: VANI Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. July 2026
Slide 2: Disclaimers
Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe ha
Slide 3: The obesity market is evolving
The obesity market is evolving What will it take to be successful in the future? In addition to the currently FDA-approved products on the market, there are over 50 in clinical development. All of these are injectables or orals. Vivani's implant uniquely combines infrequent (e.g., once- or twice-yea
Slide 4: Vivani's differentiated product candidates are designed to address unmet needs and expand the market
Vivani's differentiated product candidates are designed to address unmet needs and expand the market Market Challenges The NanoPortal™ Promise @Y Suboptimal outcomes © Convenient, guaranteed adherence Poor medication adherence (<50%) leads to Designed to maintains therapeutic effect and loss of effi
Slide 5: Vivani Medical, Inc.
Vivani Medical, Inc. A clinical stage innovator uniquely positioned to address the future challenges and opportunities of an evolving obesity market Our focus: Enhance patient outcomes and GLP-1 market uptake in chronic diseases via unique route of administration, improved patient adherence, tolerab
Slide 6: Company pipeline utilizing NanoPortal platform
Company pipeline utilizing NanoPortal platform If approved, Vivani products would provide a differentiated ultra long-acting option for patients Obesity/Weight Management NPM-139 semaglutide Obesity/Weight Management Vivani Obesity/Weight Management Type2 Diabetes Canine & Feline Obesity «Partnered
Slide 7: Good things come in small packages
Good things come in small packages GLP-1 implant & applicator ¥ Simple administration, in-office procedure to insert the implant comfortably under the skin for twice- yearly dosing designed to produce Wegovy®-level efficacy NanoPortal device elements v_ Designed to assure adherence v Long-term deliv
Slide 8: Vivani Lead Program: NPM-139
Vivani Lead Program: NPM-139 SLIM™: Semaglutide ultra Long-acting /Mplant in obesity .0Ce, Vivani
Slide 9: July 7, 2026: Vivani announces the signing of a new agreement with Novo Nordisk
July 7, 2026: Vivani announces the signing of a new agreement with Novo Nordisk 000, Vivani The agreement at a glance © Agreement enables Novo Nordisk to @ There are no exclusivity provisions for evaluate NPM-139, Vivani’s semaglutide NPM-139, or Vivani'’s proprietary drug implant for chronic weight
Slide 10: Persistence and adherence are critical to securing desired long-term health outcomes
Persistence and adherence are critical to securing desired long-term health outcomes Persistence data comparing obesity therapies suggest room for improvement across the board, including for semaglutide. The unmet need is significant. @ The opportunity for an additional 60% improvement in persistenc
Slide 11: Semaglutide discontinuation leads to rapid hunger-induced weight rebound
Semaglutide discontinuation leads to rapid hunger- induced weight rebound Sudden GLP-1 withdrawal produces immediate rebound hunger, leading to rapid weight regain mediated by greater food consumption 68-week treatment phase . 52-week off-treatment extension phase Body weight (%) — change from basel
Slide 12: NPM-139 provides steady preclinical pharmacokinetics
Viva NPM-139 provides steady preclinical pharmacokinetics In vivo pharmacokinetics of NPM-139 configurations in Sprague-Dawley rats. Values are mean + SE. *n=5 through day 28; two implants removed at Day 28 for characterization, n=3 thereafter. .00e,, 1000 800 a f=} f=) L fo} oS 200 Plasma Concentra
Slide 13: NPM-139 clinical and regulatory development: Near-term plan builds on recent wins
NPM-139 clinical and regulatory development: Near-term plan builds on recent wins Milestone Status Announced LIBERATE-1 completed and met the primary study objectives; reported positive weight loss in preclinical study with semaglutide August 2025 Disclosed proposed clinical program including Phase
Slide 14: NPM-139 Phase 1 study design: SLIM-1
NPM-139 Phase 1 study design: SLIM-1™ Primary Objectives Key Inclusion/Exclusion Criteria Safety/tolerability assessment and pharmacokinetic 18-55 years old; overweight or obese (BMI 27-40) characterization Otherwise healthy (no T2D) Screen and Treatment (4 Weeks) EOT Randomize (~21 days) Vv Vv NPM-
Slide 15: Proposed NPM-139 Phase 2 study design: SLIM-2
Proposed NPM-139 Phase 2 study design: SLIM-2™ Randomize Vv Run-In (20 weeks) Vv Randomized Treatment Period (16 or 24 weeks) < a > Semaglutide Implant Dose 3 Semaglutide Implant Dose 2 2.4mg Semaglutide Implant Dose 1 1.7mg 1.0 mg Placebo (sham implant) 0.5mg Soreehtite Wegovy® (semaglutide injecti
Slide 16: NanoPortal retatrutide implant provides steady preclinical pharmacokinetics
NanoPortal retatrutide implant provides stead = p p y @ 200. 4] 7 1 aay | N ©~ Prototype Nanoportal Retatrutide Implant, preclinical £ n=12 (through day 28), n=9 (day 28 to 56) ° ° ° 3 pharmacokinetics in gs i L — ongoing study 5 In vivo pharmacokinetics of prototype NanoPortal retatrutide a Fs impl
Slide 17: Guaranteed adherence. Improved outcomes.
Guaranteed adherence. Improved outcomes. @ Only GLP-1 implant in development for obesity and chronic weight management Convenient once- or twice-yearly dosing expected to address primary GLP-1 market challenges G @ Unique modality designed to reach underserved & unaddressed populations key to market
Slide 18: Thank You
cole. Vivani: Nasdaq: VANI Thank You Company Contact: Donald Dwyer, Chief Business Officer info@vivani.com Investor Relations Contact: Jami Taylor, Investor Relations Advisor investors@vivani.com www.vivani.com